140 related articles for article (PubMed ID: 36989963)
1. An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: A case report.
Hua Y; Huang X; Li C; Gao N
Oral Oncol; 2023 May; 140():106369. PubMed ID: 36989963
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.
Wu R; Ju Y; Long T; Su Z; Zhu G; Liu S
Transl Cancer Res; 2022 Aug; 11(8):2940-2945. PubMed ID: 36093549
[TBL] [Abstract][Full Text] [Related]
3. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
Wang F; Qin S; Sun X; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Yan P; Zou J
J Hematol Oncol; 2020 May; 13(1):47. PubMed ID: 32393323
[TBL] [Abstract][Full Text] [Related]
4. A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient.
Lin Y; Lin Y; Zhong X; Chen Q; Tang S; Chen J
Front Oncol; 2023; 13():1280208. PubMed ID: 38090483
[TBL] [Abstract][Full Text] [Related]
5. Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma.
Ma R; Wang JL; Wang YY
Exp Hematol Oncol; 2022 Oct; 11(1):78. PubMed ID: 36289520
[TBL] [Abstract][Full Text] [Related]
6. A 67-Year-Old Man with Grade 3 Reactive Cutaneous Capillary Endothelial Proliferation Induced by Camrelizumab First Manifested in the Oral Mucosa - A Case Report.
Liu Y; Liu H; Bian Q; Guan Y
Int J Surg Pathol; 2024 Jun; 32(4):803-809. PubMed ID: 37723943
[TBL] [Abstract][Full Text] [Related]
7. Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Ding Q; Liu Y; Ju H; Song H; Xiao Y; Liu X; Ren G; Wei D
Med Oral Patol Oral Cir Bucal; 2023 Nov; 28(6):e525-e529. PubMed ID: 37330963
[TBL] [Abstract][Full Text] [Related]
8. Nasal alar metastasis of advanced hepatocellular carcinoma misdiagnosed as reactive cutaneous capillary endothelial proliferation in a patient treated with camrelizumab and apatinib: a case report.
Liu J; Cao G; Zhang G; Liu S; Shi D
J Gastrointest Oncol; 2023 Jun; 14(3):1643-1649. PubMed ID: 37435210
[TBL] [Abstract][Full Text] [Related]
9. Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China.
Qu W; Wang F; Qin S; Sun Y; Huang C
Ther Adv Med Oncol; 2024; 16():17588359241242607. PubMed ID: 38606164
[TBL] [Abstract][Full Text] [Related]
10. A case report of thalidomide in the treatment of camrelizumab-induced reactive cutaneous capillary hyperplasia.
Fu S; Li C; Wang Z; Zhong Z; Zhong Y
Medicine (Baltimore); 2023 Jun; 102(26):e34120. PubMed ID: 37390264
[TBL] [Abstract][Full Text] [Related]
11. Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab: Sixteen Case Reports.
Hui-Mei P; Guang-Ming H; Xiao-Ling Q; Hong-Liang Z; Si-Jun W
Indian J Dermatol; 2023; 68(3):318-326. PubMed ID: 37529461
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation.
Song G; Zhang FF; Cheng HD
Australas J Dermatol; 2022 May; 63(2):217-221. PubMed ID: 35229882
[TBL] [Abstract][Full Text] [Related]
13. Risk of reactive cutaneous capillary endothelial proliferation induced by camrelizumab in patients with non-small cell lung cancer: a retrospective study.
He X; Fang J; Yu P; Hu W; Zhang Q; Zhang Z; Zhou M; Wang X; Bian X
J Thorac Dis; 2023 Dec; 15(12):6687-6696. PubMed ID: 38249866
[TBL] [Abstract][Full Text] [Related]
14. Camrelizumab-induced oral lichenoid reaction with subepithelial CD4+ T-cell infiltration.
Wang X; Fu T; Sun W
J Oncol Pharm Pract; 2024 Jan; 30(1):228-234. PubMed ID: 37817675
[TBL] [Abstract][Full Text] [Related]
15. Complete remission of reactive cutaneous capillary endothelial proliferation caused by the programmed cell death-1 inhibitor camrelizumab achieved through thalidomide monotherapy: A case report.
Wang C; Lei K; Jia Y; Jiang Z; Wang S
Exp Ther Med; 2023 Jul; 26(1):324. PubMed ID: 37346410
[TBL] [Abstract][Full Text] [Related]
16. Emerging Treatments for Reactive Cutaneous Capillary Endothelial Proliferation.
Liu Y; Chen T; Zhang C; Pan W
Indian J Dermatol; 2023; 68(1):85-90. PubMed ID: 37151267
[TBL] [Abstract][Full Text] [Related]
17. Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.
Yin L; Liu KC; Lv WF; Xu SB; Lu D; Zhou CZ; Cheng DL; Gao ZG; Shi CS; Su MX
Drug Des Devel Ther; 2022; 16():3421-3429. PubMed ID: 36203820
[TBL] [Abstract][Full Text] [Related]
18. Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report.
Yu Q; Wang WX
World J Clin Cases; 2020 Feb; 8(3):624-629. PubMed ID: 32110675
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma.
Ju H; Wei D; Wu Y; Liu Y; Ding Q; Rui M; Fan Z; Yao Y; Hu J; Ren G
MedComm (2020); 2023 Aug; 4(4):e312. PubMed ID: 37492783
[TBL] [Abstract][Full Text] [Related]
20. A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report.
Chen Y; Zhang H; Shi J; Wang T
Onco Targets Ther; 2020; 13():12471-12476. PubMed ID: 33299330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
